Which Institutions Own Shares In VistaGen Therapeutics Inc. (VTGN)?

29 institutions hold shares in VistaGen Therapeutics Inc. (VTGN), with 6.35M shares held by insiders accounting for 4.48% while institutional investors hold 7.88% of the company’s shares. The shares outstanding are 138.54M, and float is at 109.05M with Short Float at 4.94%. Institutions hold 7.53% of the Float.


The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored


Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

The top institutional shareholder in the company is Franklin Resources, Inc. with over 6.24 million shares valued at $12.11 million. The investor’s holdings represent 4.50% of the VTGN Shares outstanding. As of Sep 29, 2020, the second largest holder is Vanguard Group, Inc. (The) with 1.95 million shares valued at $1.36 million to account for 1.40% of the shares outstanding. The other top investors are Granite Point Capital Management, L.P. which holds 0.97 million shares representing 0.70% and valued at over $1.88 million, while Renaissance Technologies, LLC holds 0.60% of the shares totaling 0.83 million with a market value of $1.62 million.

VistaGen Therapeutics Inc. (NASDAQ: VTGN) is 52.58% higher on its value in year-to-date trading and has touched a low of $0.30 and a high of $2.94 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The VTGN stock was last observed hovering at around $2.48 in the last trading session, with the day’s gains setting it 0.48% off its average median price target of $6.00 for the next 12 months. It is also 50.67% off the consensus price target high of $6.00 offered by 4 analysts, but current levels are 40.8% higher than the price target low of $5.00 for the same period.

Currently trading at $2.96, the stock is 39.69% and 64.43% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 20.04 million and changing 19.35% at the moment leaves the stock 216.56% off its SMA200. VTGN registered 333.83% gain for a year compared to 6-month gain of 303.49%. The firm has a 50-day simple moving average (SMA 50) of $2.1933 and a 200-day simple moving average (SMA200) of $1.1324.

The stock witnessed a 29.82% loss in the last 1 month and extending the period to 3 months gives it a 312.31%, and is 49.49% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 15.10% over the week and 12.31% over the month.

VistaGen Therapeutics Inc. (VTGN) has around 9 employees, a market worth around $351.41M and $0.60M in sales. Distance from 52-week low is 886.67% and 0.68% from its 52-week high.

VistaGen Therapeutics Inc. (VTGN) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for VistaGen Therapeutics Inc. (VTGN) is a “Buy”. 4 analysts offering their recommendations for the stock have an average rating of 1.50, where 0 rate it as a Hold and 0 think it is a “Overweight”. 4 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

VistaGen Therapeutics Inc. is expected to release its quarterly report on 06/29/2021 and quarterly earnings per share for the current quarter are estimated at -$0.04 with sales reaching $230k over the same period.The EPS is expected to grow by 44.20% this year.

VistaGen Therapeutics Inc. (VTGN) Insider Activity

A total of 4 insider transactions have happened at VistaGen Therapeutics Inc. (VTGN) in the last six months, with sales accounting for 0 and purchases happening 4 times. The most recent transaction is an insider purchase by SAXE JON S, the company’s Director. SEC filings show that SAXE JON S bought 30,000 shares of the company’s common stock on Aug 21 at a price of $0.69 per share for a total of $20700.0. Following the purchase, the insider now owns 50000.0 shares.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

VistaGen Therapeutics Inc. (VTGN): Who are the competitors?

The company’s main competitors (and peers) include Iovance Biotherapeutics Inc. (IOVA) that is trading 89.67% up over the past 12 months. Short interest in the company’s stock has risen 35.44% from the last report on Dec 30, 2020 to stand at a total of 3.48 million short shares sold with a short interest ratio of 1.48.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free